<?xml version='1.0' encoding='utf-8'?>
<document id="22766462"><sentence text="Application of quantitative time-lapse imaging (QTLI) for evaluation of Mrp2-based drug-drug interaction induced by liver metabolites." /><sentence text="We previously reported a quantitative time-lapse imaging (QTLI)-based analysis method to assess drug-drug interactions (DDI) at multidrug resistance-associated protein 2 (Mrp2) in rat sandwich-cultured hepatocyte (SCH) system, utilizing the fluorescent Mrp2 substrate, 5-(and 6)-carboxy-2',7'-dichlorofluorescein (CDF)" /><sentence text=" Here, we aimed to examine the feasibility of using QTLI to evaluate DDI involving drug metabolite(s) generated in hepatocytes" /><sentence text=" We used estradiol (E2) and bilirubin as model compounds; both are not substrates of MRP2, whereas their hepatic metabolites, estradiol-17β-glucuronide (E17G) or bilirubin glucuronides, are known to be its substrates as well as inhibitors"><entity charOffset="9-18" id="DDI-PubMed.22766462.s4.e0" text="estradiol" /><entity charOffset="28-37" id="DDI-PubMed.22766462.s4.e1" text="bilirubin" /><entity charOffset="126-151" id="DDI-PubMed.22766462.s4.e2" text="estradiol-17β-glucuronide" /><entity charOffset="153-157" id="DDI-PubMed.22766462.s4.e3" text="E17G" /><entity charOffset="162-184" id="DDI-PubMed.22766462.s4.e4" text="bilirubin glucuronides" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e0" e2="DDI-PubMed.22766462.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e0" e2="DDI-PubMed.22766462.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e0" e2="DDI-PubMed.22766462.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e0" e2="DDI-PubMed.22766462.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e0" e2="DDI-PubMed.22766462.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e1" e2="DDI-PubMed.22766462.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e1" e2="DDI-PubMed.22766462.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e1" e2="DDI-PubMed.22766462.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e1" e2="DDI-PubMed.22766462.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e2" e2="DDI-PubMed.22766462.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e2" e2="DDI-PubMed.22766462.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e2" e2="DDI-PubMed.22766462.s4.e4" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e3" e2="DDI-PubMed.22766462.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22766462.s4.e3" e2="DDI-PubMed.22766462.s4.e4" /></sentence><sentence text=" When rat SCHs were pre-exposed with E2, fluorescence of CDF accumulated in bile canaliculi decreased depending upon both the duration of pre-exposure and the concentration of extracellular E2" /><sentence text=" The decrease corresponded with the increase in intracellular concentration of E17G in hepatocytes"><entity charOffset="79-100" id="DDI-PubMed.22766462.s6.e0" text="E17G" /></sentence><sentence text=" Furthermore, cytotoxicity of vinblastine, a substrate of MRP2, was enhanced in SCHs treated with E2"><entity charOffset="30-41" id="DDI-PubMed.22766462.s7.e0" text="vinblastine" /></sentence><sentence text=" Similarly, CDF accumulated in bile canaliculi was significantly reduced in rat SCHs pre-exposed with bilirubin"><entity charOffset="102-111" id="DDI-PubMed.22766462.s8.e0" text="bilirubin" /></sentence><sentence text=" In conclusion, these results suggest that phase II biotransformation of a competitor is reflected in alteration of MRP2-mediated CDF transport detected in QTLI" /><sentence text=" The QTLI might provide a convenient platform to evaluate transporter-based DDIs involving hepatic metabolites of drug candidates without the need to identify the metabolites" /><sentence text="" /></document>